FDA Approves Zevra Therapeutics’ Arimoclomol as First Treatment for Niemann-Pick Disease Type C

Zevra Therapeutics plans to immediately start its launch activities for arimoclomol, marketed as Miplyffa, which is anticipated to be commercially available in 8 to 12 weeks in the United States.:

Source: Neurology Read More

Previous PostFDA Approves Stand-Alone Thearpy Levacetylleucine for Niemann-Pick Disease Type C
Next PostUsing the DAAE Score to Advance Personalized Medicine for Multiple Sclerosis: Tom Fuchs, MD, PhD

FDA Approves Zevra Therapeutics’ Arimoclomol as First Treatment for Niemann-Pick Disease Type C

Previous PostFDA Approves Stand-Alone Thearpy Levacetylleucine for Niemann-Pick Disease Type C

Next PostUsing the DAAE Score to Advance Personalized Medicine for Multiple Sclerosis: Tom Fuchs, MD, PhD

Related Posts

<![CDATA[Seizures May Signal Occult Cancer Risk, Clene Moves Toward NDA Filing for CNM-Au8, the Future of Friedreich Ataxia Care]]>

<![CDATA[Efgartigimod Gains FDA Approval as First Treatment for Seronegative Forms of Myasthenia Gravis]]>

<![CDATA[FDA Approves Ocrelizumab for Pediatric Patients With Relapsing-Remitting Multiple Sclerosis]]>

Categories